GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Investments And Advances

LumiraDx (LumiraDx) Investments And Advances : $11.53 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Investments And Advances?

LumiraDx's Investments And Advances for the quarter that ended in Jun. 2023 was $11.53 Mil.

LumiraDx's quarterly Investments And Advances increased from Dec. 2022 ($11.42 Mil) to Mar. 2023 ($12.00 Mil) but then declined from Mar. 2023 ($12.00 Mil) to Jun. 2023 ($11.53 Mil).

LumiraDx's annual Investments And Advances stayed the same from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($11.42 Mil).


LumiraDx Investments And Advances Historical Data

The historical data trend for LumiraDx's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Investments And Advances Chart

LumiraDx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Investments And Advances
- - - 11.42

LumiraDx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 11.42 12.00 11.53

LumiraDx Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


LumiraDx (LumiraDx) Business Description

Traded in Other Exchanges
Address
C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108
LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.